| Literature DB >> 35202111 |
Léonie Dopavogui1, Arnaud Polizzi1, Anne Fougerat1, Pascal Gourbeyre1, Chloé Terciolo1, Wendy Klement1, Philippe Pinton1, Joëlle Laffite1, Anne-Marie Cossalter1, Jean-Denis Bailly1, Olivier Puel1, Yannick Lippi1, Claire Naylies1, Hervé Guillou1, Isabelle P Oswald1, Nicolas Loiseau1.
Abstract
Fumonisin B1 (FB1) is a widespread mycotoxin produced by fungal Fusarium species-mainly in maize, one of the plants most commonly used for food and feed. Pigs and horses are the animal species most susceptible to this mycotoxin. FB1 exposure can cause highly diverse clinical symptoms, including hepatotoxicity, immunotoxicity, and intestinal barrier function disturbance. Inhibition of ceramide synthetase is a well-understood ubiquitous molecular mechanism of FB1 toxicity, but other more tissue-specific effects remain to be elucidated. To investigate the effects of FB1 in different exposed tissues, we cross-analyzed the transcriptomes of fours organs: liver, jejunum, jejunal Peyer's patches, and spleen. During a four-week study period, pigs were fed a control diet or a FB1-contaminated diet (10 mg/kg feed). In response to oral FB1 exposure, we observed common biological processes in the four organs, including predominant and recurrent processes (extracellular matrix organization, integrin activation, granulocyte chemotaxis, neutrophil migration, and lipid and sterol homeostasis), as well as more tissue-specific processes that appeared to be related to lipid outcomes (cell cycle regulation in jejunum, and gluconeogenesis in liver).Entities:
Keywords: Peyer’s patches; fumonisin; jejunum; liver; spleen; swine
Mesh:
Substances:
Year: 2022 PMID: 35202111 PMCID: PMC8875869 DOI: 10.3390/toxins14020083
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Summary of significant genes (including non-annotated genes) regarding the fold change (FC) threshold for an adjusted p value < 0.05. To determine which biological processes are specifically involved in each FB1-exposed tissue, the subsequent analyses focused on genes with a FC > 1.5.
| Comparison | FC > 1.0 | FC > 1.2 | FC > 1.5 | FC > 2 | FC > 4 | FC > 6 | FC > 10 | |
|---|---|---|---|---|---|---|---|---|
| Jejunum FB1- | Up | 1536 | 1521 | 538 | 71 | 7 | 4 | 1 |
| Down | 1172 | 1168 | 715 | 193 | 17 | 3 | 0 | |
| Total | 2708 | 2689 | 1253 | 264 | 24 | 7 | 1 | |
| Liver FB1- | Up | 477 | 477 | 241 | 81 | 10 | 4 | 2 |
| Down | 454 | 454 | 194 | 102 | 12 | 2 | 2 | |
| Total | 931 | 931 | 435 | 183 | 22 | 6 | 4 | |
| Peyer FB1- | Up | 154 | 154 | 123 | 38 | 3 | 0 | 0 |
| Down | 73 | 73 | 62 | 17 | 2 | 0 | 0 | |
| Total | 227 | 227 | 185 | 55 | 5 | 0 | 0 | |
| Spleen FB1- | Up | 53 | 53 | 33 | 10 | 1 | 0 | 0 |
| Down | 81 | 81 | 73 | 44 | 19 | 7 | 3 | |
| Total | 134 | 134 | 106 | 54 | 20 | 7 | 3 |
Figure 1Comparison of transcriptomic gene expression profiling in the four studied tissues (jejunum, liver, Peyer’s patches, and spleen) under FB1 exposure. (A–D) Volcano plots show differences in gene expression between control (CTRL)- and FB1-exposed animals in: jejunum (A), liver (B), Peyer’s patches (C), and spleen (D). Red indicates p value < 0.05 and Log2 (fold change) >1.5. Grey indicates p value < 0.05 and Log2 (fold change) <1.5. Blue indicates p value > 0.05 and Log2 (fold change) > 1.5. Green indicates p value >0.05 and Log2 (fold change) <1.5. (E–H) Bar plots of the 20 upregulated and the 20 downregulated genes with the highest fold change in jejunum (E), liver (F), Peyer’s patches (G), and spleen (H).
Figure 2Overlapping of the significantly modulated gene sets between the four studied tissues, and characterization of the specificity ratio. Only annotated genes have been considered. (A,B) Venn diagram analysis of the upregulated (A) and the downregulated (B) genes (FC > 1.5 and p < 0.05) in the four tissues of FB1-exposed animals. (C) Recapitulative table of the numbers of genes specifically regulated in each tissue.
The top 10 biological processes in terms of Gene Ontology enrichments performed using Enrichr online tools, from common upregulated genes (a) and the common downregulated genes (b).
| Term | Overlap | Adjusted | Genes | Ref |
|---|---|---|---|---|
| Common upregulated genes ( | ||||
| triglyceride homeostasis (GO:0070328) | 4/31 | 0.003 | HNF4A; NR1H4; LPL; APOE | [ |
| cholesterol homeostasis (GO:0042632) | 5/71 | 0.003 | FABP3; HNF4A; LPL; APOE; NR1D1 | [ |
| sterol homeostasis (GO:0055092) | 5/72 | 0.003 | FABP3; HNF4A; LPL; APOE; NR1D1 | [ |
| sulfur compound biosynthetic process (GO:0044272) | 5/113 | 0.019 | GSTA4; CTH; MGST1; GCLM; PAPSS2 | [ |
| acylglycerol homeostasis (GO:0055090) | 3/25 | 0.023 | HNF4A; LPL; APOE | [ |
| regulation of primary metabolic process (GO:0080090) | 5/130 | 0.027 | NQO1; HNF4A; FASN; APOE; NR1D1 | [ |
| apoptotic mitochondrial changes (GO:0008637) | 3/33 | 0.036 | BAD; ATP2A1; SFN | [ |
| positive regulation of phospholipid biosynthetic process (GO:0071073) | 2/7 | 0.036 | FABP3; NR1H4 | [ |
| negative regulation of defense response (GO:0031348) | 5/85 | 0.036 | NR1H4; APOE; NR1D1; KLF4 | [ |
| sodium ion transmembrane transport (GO:0035725) | 5/87 | 0.036 | SCN8A; SCNN1A; ATP1B1; SLC6A3 | [ |
| Common downregulated genes ( | ||||
| extracellular matrix organization (GO:0030198) | 27/300 | 5.46 × 10−22 | COL15A1; COL16A1; SPARC; ECM2; COL14A1; COL12A1; HTRA1; DPT; LAMC1; LOXL2; FLRT2; SERPINH1; ITGAV; POSTN; FN1; DCN; COL1A1; GREM1; COL3A1; BMP1; COL1A2; LOX; MMP16; COL4A1; COL5A2; COL6A3; FBN1 | [ |
| collagen fibril organization (GO:0030199) | 16/89 | 2.63 × 10−17 | COL15A1; COL16A1; COL14A1; COL12A1; DPT; LOXL2; GREM1; COL1A1; COL3A1; BMP1; COL1A2; LOX; COL4A1; COL5A2; SERPINH1; COL6A3 | [ |
| supramolecular fiber organization (GO:0097435) | 22/351 | 9.89 × 10−15 | COL15A1; COL16A1; TNXB; COL14A1; COL12A1; TPM1; STMN2; DPT; LOXL2; COL1A1; GREM1; EFEMP2; COL3A1; BMP1; COL1A2; ACTC1; LOX; COL4A1; COL5A2; SERPINH1; COL6A3; EMILIN1 | [ |
| cellular protein metabolic process (GO:0044267) | 12/147 | 7.14 × 10−4 | IL6; RCN1;L GALS1; LOX; SDC2; IGFBP2; FN1; IGFBP7; LAMC1; FSTL1; LOXL2; FBN1 | [ |
| integrin activation (GO:0033622) | 5/8 | 0.0012 | COL16A1; CXCL12; FN1 | [ |
| positive regulation of cellular process (GO:0048522) | 13/625 | 0.0047 | SLC30A2; TPM1; FN1; HBB; GREM1; IL6; CXCL12; CXCR2; ITGAV; S100A9; SOX4; S100A8; TLR2 | [ |
| granulocyte chemotaxis (GO:0071621) | 5/73 | 0.0047 | CXCR2; CCL2; S100A12; S100A9; S100A8 | [ |
| positive regulation of macromolecule metabolic process (GO:0010604) | 10/384 | 0.0047 | GREM1; ACTA2; GJA1; IL6; ACTC1; FN1; EMILIN1; ANK3; ROBO1; TLR2 | [ |
| endothelial cell migration (GO:0043542) | 4/39 | 0.0047 | PLXND1; FAP; FSTL1; LOXL2 | [ |
| neutrophil migration (GO:1990266) | 5/77 | 0.0049 | CXCR2; CCL2; S100A12; S100A9; S100A8 | [ |
Figure 3Effect of FB1 exposure on pertinent genes expression in the four studied tissues (jejunum, liver, Peyer’s patches, and spleen). Bar plots of some typical upregulated and downregulated genes representative of common biological processes present in the four studied tissues. Colors indicate the results according the tissue. Plotted data represent the mean ± SD of six animals.
Figure 4Determination of specific biological processes found in the four studied tissues (jejunum, liver, Peyer’s patches, and spleen). Balloon plots present the results of the hypergeometric test performed on biological processes identified from gene ontology analysis based on upregulated genes (A), and downregulated genes (B). Sizes indicate the Log2 (number of genes) associated with the indicated biological process. Colors indicate the hypergeometric test -Log10 (p value), from violet for low-confidence results to shiny blue for high-confidence results.